This review recapitulates the underlying mechanisms contributing to the inferior clinical outcomes of anti-PD-1/PD-L1 immune-checkpoint inhibitors (ICIs) in NSCLC patients bearing EGFR mutations. This evidence concerns the gene CD274 and non-small cell lung carcinoma.